SCHEMBL43970

SCHEMBL43970

CCCCC(C(=O)O)N1C(=O)C=CC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 9/20 0.42
MAPK1 P28482 2/20 0.41
CA2 P00918 1/20 0.41
DNMT1 P26358 1/20 0.40
PTGS1 P23219 3/20 0.39
PTGS2 P35354 3/20 0.39
MGLL Q99685 2/20 0.39
FAAH O00519 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
GLA P06280 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
NFKB1 P19838 1/20 0.38
APEX1 P27695 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4277446 0.98 PTPN1 (0.41) PTPN1MAPK1CA2DNMT1PTGS1
SCHEMBL6939609 0.95 GPR84 (0.43) PTPN1MAPK1DNMT1PTGS1PTGS2
SCHEMBL6940135 0.93 GPR84 (0.46) DNMT1PTGS1PTGS2MGLLFAAH
SCHEMBL1574549 0.93 GPR84 (0.46) DNMT1PTGS1PTGS2MGLLFAAH
SCHEMBL6934782 0.93 GPR84 (0.46) DNMT1PTGS1PTGS2MGLLFAAH
SCHEMBL43883 0.93 GPR84 (0.46) DNMT1PTGS1PTGS2MGLLFAAH
SCHEMBL30634818 0.93 GPR84 (0.46) DNMT1PTGS1PTGS2MGLLFAAH
Hydrochloric Acid SCHEMBL6934814 0.92 GPR84 (0.44) DNMT1PTGS1PTGS2MGLLFAAH
SCHEMBL258485 0.92 GPR84 (0.44) DNMT1PTGS1PTGS2MGLLFAAH
SCHEMBL258604 0.92 GPR84 (0.44) DNMT1PTGS1PTGS2MGLLFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319171-A1 COMPOSITIONS AND METHODS FOR PREVENTING TUMORS AND CANCER CANCER ADVANCES INC. (US) 2025-10-16 US claimed
US-20250242007-A1 COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER CANCER ADVANCES INC. (US) 2025-07-31 US claimed
CN-119912833-A Asphalt coating material, preparation method thereof and double-base asphalt waterproof coiled material 河北宇阳泽丽防水材料有限公司 2025-05-02 CN claimed
CN-119823209-A Synthesis method of cyclic peptide containing maleimide acid 江苏金斯瑞生物科技有限公司 2025-04-15 CN claimed
US-20250073175-A1 Intra-Dosage Form Coatings and Applications Thereof BALCHEM CORPORATION 2025-03-06 US claimed
US-20250042846-A1 METHOD FOR PREPARING A SULFUR OR SELENISED COMPOUND BY THIOLENE REACTION ADISSEO FRANCE S.A.S. (FR) 2025-02-06 US claimed
EP-4489731-A2 INTRA-DOSAGE FORM COATINGS AND APPLICATIONS THEREOF Balchem Corporation (US) 2025-01-15 EP claimed
CN-119264155-A Latent curing agent based on dynamic crosslinking-controllable dissolution mechanism 江南大学 2025-01-07 CN claimed
CN-119185587-A Enhanced penetration type dual-response nanoparticle for co-delivering chemotherapeutic drugs and gene drugs, and preparation method and application thereof 复旦大学 2024-12-27 CN claimed
WO-2024258015-A1 METHOD FOR MANUFACTURING HYDROGEL FOR THREE-DIMENSIONAL CELL CULTURE, CAPABLE OF CONTROLLING OXYGEN CONCENTRATION, AND METHOD FOR CONSTRUCTING DISEASE MODEL 인천대학교 산학협력단 2024-12-19 WO claimed
WO-2009070640-A2 METHODS AND COMPOSITIONS FOR AMPLIFYING A DETECTABLE SIGNAL GREAT BASIN SCIENTIFIC (US) 2009-06-04 WO claimed
US-20090098076-A1 Method For the Production of a Keratin-Binding Effector Molecule BASF SE (DE) 2009-04-16 US claimed
JP-2009508852-A 2009-03-05 JP claimed
US-20080286688-A1 Photosensitive Resin Composition and Cured Product Thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2008-11-20 US claimed
EP-1973952-A1 CONJUGATE COMPRISING PHARMACEUTICAL ACTIVE COMPOUND COVALENTLY BOUND TO MUCOADHESIVE POLYMER AND TRANSMUCOSAL DELIVERY METHOD OF PHARMACEUTICAL ACTIVE COMPOUND USING THE SAME Gwangju Institute of Science and Technology (KR) 2008-10-01 EP claimed
WO-2008049643-A2 GD2 PEPTIDE MIMOTOPES FOR ANTICANCER VACCINATION CHARITE - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2008-05-02 WO claimed
WO-2007083984-A1 CONJUGATE COMPRISING PHARMACEUTICAL ACTIVE COMPOUND COVALENTLY BOUND TO MUCOADHESIVE POLYMER AND TRANSMUCOSAL DELIVERY METHOD OF PHARMACEUTICAL ACTIVE COMPOUND USING THE SAME GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2007-07-26 WO claimed
EP-1710626-A1 PHOTOSENSITIVE RESIN COMPOSITION AND CURED PRODUCT THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2006-10-11 EP claimed
EP-0665020-A2 Method for preparing thioether conjugates BRISTOL-MYERS SQUIBB COMPANY (US) 1995-08-02 EP claimed
US-5073611-A Containing photoreactive compound capable of abstracting hydrogen; coatings, hot melt adhesives BASF AKTIENGESELLSCHAFT (DE) 1991-12-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042846-A1 METHOD FOR PREPARING A SULFUR OR SELENISED COMPOUND BY THIOLENE REACTION SCLY, TST, SELENOI PTPN1 3784/4885MAPK1 1805/4885CA2 3289/4885
US-20090098076-A1 Method For the Production of a Keratin-Binding Effector Molecule KRT18, KRTCAP2, CUTA PTPN1 4276/4885MAPK1 3547/4885CA2 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.